Excellent results.
The way that the announcement is written, I'm unsure whether the SD and PR are independent of each other. If they are, then this appears to be a little sleeper - 85% DCR.
From what I can tell, they've simply run a P1b/2a that mimicks the below P3 trial and just added Narmafotinib. Unsure of other clinical competitors used in combination with paclitaxel/gemcitabine in advanced pancreatic cancer, but the results are compelling so far.
The next key measures are obviously OS & PFS, but that will come with time.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1304369
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.8¢ |
Change
0.003(1.06%) |
Mkt cap ! $114.3M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.5¢ | 22.5¢ | $1.205M | 5.174M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 583488 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 1059979 | 11 |
View Market Depth
| Last trade - 12.12pm 30/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |